Int J Biol Macromol, 2019, 145:216-225

Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.

Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying patients for specific biotherapeutics. New type of imaging probes, based on designed ankyrin repeat proteins (DARPins), have demonstrated excellent contrast of imaging of human epidermal growth factor type 2 (HER2) expression in preclinical models. We hypothesized that labeling approaches, which result in lipophilic radiometabolites (non-residualizing labels), would provide the best imaging contrast for DARPins that internalize slowly after binding to cancer cells. The hypothesis was tested using DARPin Ec1 that bind to epithelial cell adhesion molecule (EpCAM). EpCAM is a promising therapeutic target. Ec1 was labeled with I using two methods to obtain the non-residualizing labels, while residualizing labels were obtained by labeling it with Tc. All labeled Ec1 variants preserved target specificity and picomolar binding affinity to EpCAM-expressing pancreatic adenocarcinoma BxPC-3 cells. In murine models, all the variants provided similar tumor uptake. However, I-PIB-H-Ec1 had noticeably lower retention in normal tissues, which provided appreciably higher tumor-to-organ ratios. Furthermore, I-PIB-H-Ec1 demonstrated the highest imaging contrast in preclinical models than any other EpCAM-imaging agent tested so far. In conclusion, DARPin Ec1 in combination with a non-residualizing label is a promising probe for imaging EpCAM expression a few hours after injection.

Deyev SM, Vorobyeva A, Schulga A, Abouzayed A, Günther T, Garousi J, Konovalova E, Ding H, Gräslund T, Orlova A, Tolmachev V

IBCH: 8306
Ссылка на статью в журнале: https://linkinghub.elsevier.com/retrieve/pii/S0141813019393808
Кол-во цитирований на 07.2024: 20
Данные статьи проверены модераторами 2019-12-23

Список научных проектов, где отмечена публикация

  1. Инженерия бактериальной клетки для экспрессии токсичных генов (6 Января 2018 года — 31 Декабря 2020 года). Шульга А.А.. Грант, РФФИ.
  2. Синтез искусственных белков для биомедицины (6 Августа 2018 года — 6 Августа 2021 года). Шульга А.А.. Грант, РФФИ.
  3. Разработка адресной системы на основе анти-HER2-скаффолдов и молекулярной пары барназа-барстар для ступенчатой доставки цитотоксинов при терапии HER2-положительных злокачественных новообразований. (6 Января 2019 года — 31 Декабря 2023 года). Деев С.М., Лебеденко Е.Н., Прошкина Г.М., Шилова О.Н.. Грант, РНФ.